Bronchiectasis phenotype in COPD patients

Clinical Pulmonary Medicine

Volumn 22, Issue 3, 2015, Pages 123-127

  Martínez Garcia, Miguel A ^a   Selma Ferrer, María J ^a   Navarro Soriano, Cristina ^a   Munoz Reina, Alvaro ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

bronchiectasis; chronic obstructive pulmonary disease; clinical phenotype; COPD

Indexed keywords

GELATINASE B; TUMOR NECROSIS FACTOR ALPHA;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE PREDISPOSITION; GENE EXPRESSION; HUMAN; INFLAMMATION; LUNG LOBE; PHENOTYPE; THORAX RADIOGRAPHY;

EID: 84929323125     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0000000000000089     Document Type: Article

References (39)

1. Han MK, Bartholmai B, Liu LX, et al. Clinical significance of radiological characterizations in COPD. COPD. 2009;6:459-467.
2. Martinez-García MA, de la Rosa D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:823-831.
3. Zulueta JJ, Wisnivesky JP, Henschke CI, et al. Emphysema scores predict death from COPD and lung cancer. Chest. 2012;141:1216-1223.
4. Han MK, Agusti A, Calverley PMA, et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010;182:598-604.
5. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes in COPD. Identification, definition and implications for guidelines. Arch Bronconeumol. 2012;48:86-98.
6. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbations in chronic obstructive pulmonary disease. N Eng J Med. 2010;363: 1128-1138.
7. Casanova C, Cote C, De Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591-597.
8. Wardlaw AJ, Silverman M, Siva R, et al. Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy. 2005;35:1254-1262.
9. McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188:647-656.
10. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108:955-961.
11. Miravitlles M, Soriano JB, Garćia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863-868.
12. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007. Chest. 2012;142:432-439.
13. Weycker D, Edelsberg J, Oster G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205-209.
14. Martinez-Garcia MA, Soler-Cataluña JJ. EPOC y bronquiectasias. Arch Bronconeumol. 2010;46(suppl 3):11-17.
15. OBrien CO, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635-642.
16. Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, exacerbations indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:400-407.
17. Garcia Vidal C, Almagro P, Romani V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbations: a prospective study. Eur Respir J. 2009;34:1072-1078.
18. Agusti A, Calverley PM, Celly B, et al. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122-136.
19. Martínez-Garćia MA, Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest. 2011;140:1130-1137.
20. Bafadhel M, Umar I, Gupta S, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 2011;140:634-642.
21. Stewart JI, Maselli DJ, Anzueto A, et al. Clinical impact of CT radiological feature of bronchiectasis in the COPD Gene cohort. Am J Respir Crit Care Med. 2012;185:A3656
22. Kumar N, Lai D, Sansom B, et al. Relative impact of emphysema, bronchial wall thickening and bronchiectasis severity on lung function, infection and outcomes in COPD. Am J Respir Crit Care Med. 2012;185:A6621
23. Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiec-tasis: independent impact on disease course and outcomes. COPD. 2014;11:605-614.
24. Naidich DP, McCauley DI, Khouri NF, et al. Computed tomography of bronchiectasis. J Comput Assist Tomogr. 1982;6:437-444.
25. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha 1 antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176:1215-1221.
26. Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha 1 antitrypsin alleles in patients with bronchiectasis. Chest. 2000;117:415-419.
27. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277-1284.
28. Pasteur MC, Bilton D, Hill AT. and the British Society Bronchiec-tasis non-CF Guideline group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(suppl 1):i1-i58.
29. Vendrell M, De Gracia J, Olveira C, et al. Normativa sobre el diagnóstico y tratamiento de las bronquiectasias. Arch Bronco-neumol. 2008;44:629-640.
30. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with COPD? Heart Lung. 2006;35: 58-65.
31. Koblizek V, Chlumsky J, Zindr V, et al. Chronic obstructive pulmonary disease. Official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Palacky Olomouc Czech Repub. 2013;157:189-201.
32. ODonnell AE. Bronchiectasis in patients with COPD. A distinct COPD phenotype? Chest. 2013;140:1107-1108.
33. Stockley RA. Bronchiectasis with chronic obstrutive pulmonary disease. Association or a further phenotype? Am J Respir Crit Care Med. 2013;187:786-789.
34. Patuzzo C, Gilè LS, Zorzetto M, et al. Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest. 2000;117:1353-1358.
35. Kim WJ, Hoffman E, Relly J, et al. Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J. 2011;37:39-43.
36. Ito I, Nagai S, Handa T, et al. Matrix metalloproteinasa-9 promoter polymorphism with upper lung dominant emphysema. Am J Respir Crit Care Med. 2005;172:1378-1382.
37. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Diagnostic and management guidelines for patients with COPD. Spanish guidelines for COPD (GesEPOC). Arch Bronconeumol. 2012;48(suppl 1):1-83.
38. Matkovic Z, Miratvilles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir Med. 2013;107:10-22.
39. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7:32-43.